{"id":919098,"date":"2025-12-11T17:44:35","date_gmt":"2025-12-11T22:44:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/"},"modified":"2025-12-11T17:44:35","modified_gmt":"2025-12-11T22:44:35","slug":"investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/","title":{"rendered":"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Dec.  11, 2025  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of <strong>MoonLake Immunotherapeutics (NASDAQ: MLTX).<\/strong><\/p>\n<p>Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1BOvSOVsoBtqmLPWnveEz6BgJu9ObrR3yWSIJXvFJV1XgAcm5NdemkWXVa_18qYOTOzTAjbrYJBV_IrznkSHyDGtOljGHw80VbGp4M7M9D9CADxNFdegTc777MbkR_28u-wRWz8An9lptf0d9RTIF5YgZcBVQ4SzPBO7q2nQ9P1VaAA4qd9zxpysIPk_wKB-zzG80qYAmFAG1xaHK96YFxcy5IAqUZX0TnoTGd7Q6uuJSvgy-n-wjgc8lb92O51HeR28PDcbmiaR8q9TYV0fvZj4RRoTm483NjvwyE88uZ0=\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/moonlake-loss-submission-form\/?id=179999&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>March 10, 2024 to September 29, 2025<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK\u2019s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK\u2019s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK\u2019s purported superiority to monoclonal antibodies.<\/p>\n<p>\n        <strong>DEADLINE: December 15, 2025<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1BOvSOVsoBtqmLPWnveEz6BgJu9ObrR3yWSIJXvFJV1XgAcm5NdemkWXVa_18qYOTOzTAjbrYJBV_IrznkSHyDGtOljGHw80VbGp4M7M9D9CADxNFdegTc777MbkR_28zH9uMr8bUNHRzjsVItjeynBySpwbi9bHX90clTOLf7ZROTASczNZlFZUbY4ddI4crmLcqblBo-vZsKehHHuzusYwOLR7DQYRW0_9rc0augaRmrUzsfDkEmWKjiYsQvF2JU7dCGq0uFlIxG31nLvSGF5ji3yf8xne8UP7flGIVQY=\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/moonlake-loss-submission-form\/?id=179999&amp;from=3<\/a><\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of MLTX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 15, 2025. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DgfvLVA8fo41xx30UnHHd5QiklbANtQO8yLTQP80luZ1SJKL2jOcIM23Ls7Gzqpkkn07U1O1U3s1iLBrr9ciLKfWXJIYNuFYeCJpzhNr-K_RwqU05GvDBRC4WOnNQN9K\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a><br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGNhZjA4NjYtNjQxNC00ZTU0LTlhNTQtMmRkZDUwNWVhNTRjLTEyNzA0NjctMjAyNS0xMi0xMS1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/moonlake-loss-submission-form\/?id=179999&amp;from=3 CLASS PERIOD: March 10, 2024 to September 29, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK\u2019s distinct Nanobody structure would not confer a superior &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-919098","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action - MLTX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action - MLTX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/moonlake-loss-submission-form\/?id=179999&amp;from=3 CLASS PERIOD: March 10, 2024 to September 29, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK\u2019s distinct Nanobody structure would not confer a superior &hellip; Continue reading &quot;Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T22:44:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX\",\"datePublished\":\"2025-12-11T22:44:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/\"},\"wordCount\":401,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/\",\"name\":\"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action - MLTX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=\",\"datePublished\":\"2025-12-11T22:44:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action - MLTX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/","og_locale":"en_US","og_type":"article","og_title":"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action - MLTX - Market Newsdesk","og_description":"NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/moonlake-loss-submission-form\/?id=179999&amp;from=3 CLASS PERIOD: March 10, 2024 to September 29, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) It&#8217;s sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK\u2019s distinct Nanobody structure would not confer a superior &hellip; Continue reading \"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-11T22:44:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX","datePublished":"2025-12-11T22:44:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/"},"wordCount":401,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/","name":"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action - MLTX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=","datePublished":"2025-12-11T22:44:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwMDM1MyM3MzE2NDkzIzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investors-who-lost-money-on-moonlake-immunotherapeutics-mltx-should-contact-the-gross-law-firm-about-pending-class-action-mltx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Investors who lost money on MoonLake Immunotherapeutics (MLTX) should contact The Gross Law Firm about pending Class Action &#8211; MLTX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=919098"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/919098\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=919098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=919098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=919098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}